event that, if sustained, seems to add to the AD risk conferred by the ApoE4 gene.—Esther Landhuis. None
toxicity in primary neuronal cultures in a dose-dependent fashion.—Esther Landhuis. This concludes our
in the brain in AD and related diseases. For more on that, see Part 3 of this series.—Esther Landhuis.
For a different approach to treating tauopathy mice, see Part 2 of this series.—Esther Landhuis. This is Part 1
C-terminus—which binds Fe65 and other cytoplasmic proteins—could still mediate key APP functions.—Esther Landhuis.
with AD-like features in this study had severe dementia.—Esther Landhuis None
goes well, that is.—Esther Landhuis and Gabrielle Strobel. None
meeting in Washington, DC.—Esther Landhuis. This is a two-part story. See also Part 1. None
in the management of AD risk factors, and general advances in medical care for older people, Jones noted.—Esther
receptor antagonists.—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=1879 Alzheimer's
mechanisms.”—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=1876 Alzheimer's Disease Ion Channels
and geranylgeranylation.—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=1874 Aging Sirtuins
of facilitating AD research by clearly permitting surrogate consent.—Esther Landhuis See also Part 1
of this story.—Esther Landhuis See also Part 2 of this story. None http://www.alzforum.org/new/detail.asp?id=1867
of CNI-1493 as an AD drug.—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=1865